Literature DB >> 19700393

Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease.

James I Robinson1, Jennifer H Barrett, John C Taylor, Marc Naven, Diane Corscadden, Anne Barton, Anthony G Wilson, Paul Emery, John D Isaacs, Ann W Morgan.   

Abstract

OBJECTIVES: Genome-wide association studies in rheumatoid arthritis (RA) have failed to examine the FCGR gene cluster because of the confounding effects of segmental duplication. This study aimed to replicate previous candidate gene studies that had identified a significant association between the FCGR3A-158V allele and RA and then sought to estimate specific subgroup effects.
METHODS: FCGR3A-158F/V genotyping was undertaken in a UK Caucasian replication cohort comprising 2049 patients with RA and 1156 controls. Subgroup analyses assessing the magnitude of association according to gender and autoantibody (rheumatoid factor (RF) and cyclic citrullinated peptide (CCP)) status were undertaken in a pooled cohort of 2963 patients with RA and 1731 controls. Logistic regression was used to test for interaction between FCGR3A and HLA-DRB1 shared epitope (SE) alleles.
RESULTS: In the combined RA cohort, borderline association with homozygosity was found for the FCGR3A-158V allele (OR 1.2, p=0.05), which was stronger in men (OR 1.7, p=0.01). Stratification by autoantibody status showed an increased risk in RF and CCP positive RA. Analysis of the FCGR3A-158V and HLA-DRB1 SE interaction revealed roles for both genes in susceptibility to autoantibody positive RA, with no evidence of interaction.
CONCLUSIONS: FCGR3A is a risk factor for the development of autoantibody positive RA, particularly in men, with evidence of a multiplicative effect with HLA-DRB1 SE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19700393     DOI: 10.1136/ard.2009.110874

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  7 in total

1.  Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.

Authors:  J Stümer; M H C Biermann; J Knopf; I Magorivska; A Kastbom; A Svärd; C Janko; R Bilyy; G Schett; C Sjöwall; M Herrmann; L E Muñoz
Journal:  Clin Exp Immunol       Date:  2017-06-13       Impact factor: 4.330

Review 2.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 3.  The rheumatoid arthritis HLA-DRB1 shared epitope.

Authors:  Joseph Holoshitz
Journal:  Curr Opin Rheumatol       Date:  2010-05       Impact factor: 5.006

Review 4.  Nonendocrine mechanisms of sex bias in rheumatic diseases.

Authors:  Nathalie C Lambert
Journal:  Nat Rev Rheumatol       Date:  2019-10-09       Impact factor: 20.543

5.  FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy.

Authors:  Dawn L Cooper; Stephen G Martin; James I Robinson; Sarah L Mackie; Christopher J Charles; Jackie Nam; John D Isaacs; Paul Emery; Ann W Morgan
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 6.  Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing.

Authors:  John J Connolly; Hakon Hakonarson
Journal:  J Biomed Biotechnol       Date:  2012-05-10

7.  Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.

Authors:  Alf Kastbom; Lars Cöster; Lisbeth Arlestig; Aikaterini Chatzidionysiou; Ronald F van Vollenhoven; Leonid Padyukov; Solbritt Rantapää-Dahlqvist; Saedis Saevarsdottir
Journal:  BMJ Open       Date:  2012-09-22       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.